Harmonisation of Endocrine Dynamic Testing -Adult (HEDTA)
Growth Hormone Replacement of GH Deficiency in adults
Hormonal management of transgender and gender diverse adults
Thyroid disease during pregnancy and postpartum
Download Harmonisation of Endocrine Dynamic Testing -Adult (HEDTA)
The HEDTA manual is a joint initiative from ESA/AACB/RCPA and is freely available as a resource for Endocrinologists and Biochemists. The information provided is a guide only and needs to be verified by individual clinicians and laboratories prior to use. Modifications might be required according to local procedures (e.g., patient consent, sample type, name of test set, collection, interpretation and reporting procedures). Queries can be directed to the chair of the HEDTA working party.
The Endocrine Society of Australia (ESA) holds the view that adults with growth hormone (GH) deficiency are not normal and have impaired health. Such patients have a characteristic clinical syndrome which includes abnormal body composition, reduced physical fitness, increased cardiovascular risk factors, osteopaenia and impaired psychological function. Based on evidence that GH replacement is beneficial, the ESA endorses the principle that adults with GH deficiency should be considered for GH replacement therapy. Such patients must be accurately diagnosed. Patients with a history of organic hypothalamic-pituitary disease exhibiting characteristics of the GH deficient syndrome and who fulfil rigorous diagnostic criteria should be considered eligible for treatment.
The ESA recommends the guidelines of the Endocrine Society for the diagnosis, treatment and monitoring of GH deficient patients on GH therapy^.
The ESA does not support the use of GH in adults without GH deficiency.
Download Clinical Practice Guideline
^ Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 96: 1587-1609, 2011
During the 2017 Australian Professional Association for Trans Health Biennial Conference, the need for an Australian‐based gender‐affirming hormone‐treatment pathway was highlighted. A working group chaired by Dr Ada Cheung, reviewed relevant evidence, published guidelines and expert opinion to develop Australian guidelines. The guidelines were also informed by survey responses of Australian transgender or gender diverse adult individuals, to ascertain health needs, and current Australian prescribing patterns among the AusPATH members. The resulting guidelines provide specific recommendations for the hormonal and related management of TGD individuals aged over 18 years for Australian medical practitioners.
Find the guidelines published in the MJA here: https://www.mja.com.au/journal/2019/211/3/position-statement-hormonal-management-adult-transgender-and-gender-diverse
This toolkit for managing the menopause has been endorsed by the International Menopause Society, the Australasian Menopause Society and the Jean Hailes Foundation. It has been endorsed for global use.
The toolkit contains algorithms and supporting documents to deliver an accessible desk-top tool for health care practitioners caring for women at midlife.
The Australian PCOS Alliance published the first international evidence-based guideline for the assessment and management of PCOS in 2011, using a rigorous approach incorporating consumer participation and considered judgement of 31 expert clinicians and researchers from PCOS relevant disciplines. The guideline is endorsed by the National Health and Medical Research Council in Australia, and has been commended internationally by the NIH and incorporated into the NICE guidelines in the UK and now by the WHO.
Download the guideline: https://onlinelibrary.wiley.com/doi/10.1111/cen.13795
The official Journal of the ESA, Clinical Endocrinology, is pleased to announce publication of the latest Guidelines for the Management of Thyroid Cancer from the British Thyroid Association.
This third edition represents a comprehensive revision of the guidelines since their last update in 2006/7, involving several new contributors from a wider range of disciplines. The new edition incorporates recent evidence and promotes further the survivorship agenda by emphasising the importance of quality of life. Patient engagement and participation in decision making is highlighted. The role of new and emerging treatments in advanced disease is also included. Ultrasound of the neck performed by an expert operator is invaluable in the investigation of suspected cases of thyroid cancer and a new chapter is devoted to describing how to best utilise this technique. Additional chapters include microcarcinoma, anaplastic thyroid cancer and survivorship.
It is hoped that the document will provide guidance for general practitioners, general physicians, endocrinologists, surgeons, oncologists, nuclear medicine physicians, radiologists, pathologists, medical physicists, biochemists and nurses, as well as those involved in managerial roles. The guidelines are also intended to provide a basis for local and national audits.
Special Issue: British Thyroid Association Guidelines for the Management of Thyroid Cancer (2014), Clinical Endocrinology, 81(s1), 1-136.
The 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease during Pregnancy and the Postpartum has been published in the Thyroid journal.
Endocrine Society of Australia
145 Macquarie Street
Sydney. NSW. 2000
Email: ijohnson@endocrinesociety.org.au
The Endocrine Society of Australia acknowledges the Australian Aboriginal and Torres Strait Islander peoples as the first inhabitants of the nation and the traditional custodians of the lands where we live, learn and work. We pay our respects to their Elders past, present and emerging.
